Hemostemix Announces Voting Results of the Annual and Special Meeting of ShareholdersSeptember 27, 2018
CALGARY, Alberta, Sept. 27, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders (the “Meeting”) held on September 26, 2018, shareholders overwhelmingly approved all the resolutions placed before the Meeting and as outlined in the Management Information Circular dated August 22, 2018. Angus H. Jenkins, David L. Wood and Donald E. Friesen were all re-elected as
the Company’s board of directors.
The Company is sincerely appreciative of the support of its shareholders as it works towards achieving its clinical trial goals and business objectives with an overall objective of enhancing value for all of its shareholders.
To download full news release Click Here.
View All News & Media